This randomized, phase II/III trial studies how well standard-of-care therapy with stereotactic radiosurgery and/or surgery works and compares it to standard-of-care therapy alone in treating patients with breast cancer that has spread to one or two locations in the body (limited metastatic) that are previously untreated. Standard-of-care therapy comprising chemotherapy, hormonal therapy, biological therapy, and others may help stop the spread of tumor cells. Radiation therapy and/or surgery is usually only given with standard-of-care therapy to relieve pain. However, in patients with limited metastatic breast cancer, stereotactic radiosurgery, also known as stereotactic body radiation therapy (SBRT), may be able to send x-rays directly to the tumor and cause less damage to normal tissue and surgery may be able to effectively remove the metastatic tumor cells. It is not yet known whether standard-of-care therapy is more effective with stereotactic radiosurgery and/or surgery in treating limited metastatic breast cancer.
Accepting new patients
The primary objective of this clinical trial is progression-free survival.
Note: This is only a partial list of eligibility criteria.
Including patients who:
Excluding patients who:
Accepting new patients
Learn more at
Principal Investigator(s)